SZLSF (StageZero Life Sciences) Total Assets : $0.58 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences Total Assets?

StageZero Life Sciences's Total Assets for the quarter that ended in Sep. 2024 was $0.58 Mil.

During the past 12 months, StageZero Life Sciences's average Total Assets Growth Rate was -19.90% per year. During the past 3 years, the average Total Assets Growth Rate was -28.00% per year. During the past 5 years, the average Total Assets Growth Rate was 2.00% per year. During the past 10 years, the average Total Assets Growth Rate was 23.80% per year.

During the past 13 years, StageZero Life Sciences's highest 3-Year average Total Assets Growth Rate was 418.40%. The lowest was -62.30%. And the median was 1.35%.

Total Assets is connected with ROA %. StageZero Life Sciences's annualized ROA % for the quarter that ended in Sep. 2024 was -273.99%. Total Assets is also linked to Revenue through Asset Turnover. StageZero Life Sciences's Asset Turnover for the quarter that ended in Sep. 2024 was 0.86.

StageZero Life Sciences Total Assets Historical Data

The historical data trend for StageZero Life Sciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Total Assets Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

1.45

1.97

8.51

10.65

0.70

StageZero Life Sciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															0.78	0.51	0.38	0.58	0.58

StageZero Life Sciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

StageZero Life Sciences's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	-7.503	+	8.204
	=	0.70

StageZero Life Sciences's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	-11.126	+	11.707
	=	0.58

StageZero Life Sciences (OTCPK:SZLSF) Total Assets Explanation

Total Assets is connected with ROA %.

StageZero Life Sciences's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-1.596	/	( (0.584	+	0.581)	/ 2 )
	=	-1.596	/	0.5825
	=	-273.99 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

StageZero Life Sciences's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	0.5	/	( (0.584	+	0.581)	/ 2 )
=	0.5	/	0.5825
=	0.86

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

StageZero Life Sciences Total Assets Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.